Nelfinavir (Mesylate)

Nelfinavir Mesylate (AG 1343 Mesylate) is a potent and orally bioavailable HIV-1 protease inhibitor (Ki=2 nM) for HIV infection. Nelfinavir Mesylate (AG 1343 Mesylate) is a broad-spectrum, anticancer agent[1][2][3].

Product Specifications

CAS Number

[159989-65-8]

Product Name Alternative

AG 1343 Mesylate

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

HIV; HIV Protease

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/Nelfinavir-Mesylate.html

Purity

98.93

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

[H][C@]12C[C@@H](C(NC(C)(C)C)=O)N(C[C@H]([C@@H](NC(C3=C(C)C(O)=CC=C3)=O)CSC4=CC=CC=C4)O)C[C@@]1([H])CCCC2.CS(=O)(O)=O

Molecular Formula

C33H49N3O7S2

Molecular Weight

663.89

Precautions

H302, H315, H319, H335

References & Citations

[1]Mondal D, et al. Nelfinavir suppresses signaling and nitric oxide production by human aortic endothelial cells: protective effects of thiazolidinediones. Ochsner J. 2013 Spring;13 (1) :76-90.|[2]Kaldor SW, et al. Nelfinavir mesylate (AG1343) : a potent, orally bioavailable inhibitor of HIV-1 protease. J Med Chem. 1997 Nov 21;40 (24) :3979-85.|[3]Gills JJ, et al. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that inducesendoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res. 2007 Sep 1;13 (17) :5183-94.|[4]Bono C, et al. The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo. Haematologica. 2012;97 (7) :1101‐1109.|[5]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6 (1) :212.